TABLE 4

Variables predicting survival in patients with interstitial pneumonia with autoimmune features

CharacteristicUnadjusted#Adjusted#
HR (95% CI)p-valueHR (95% CI)p-value
Age1.06 (1.03–1.08)<0.0011.05 (1.02–1.08)0.001
Male sex1.54 (0.91–2.60)0.111.65 (0.92–2.97)0.09
Hypothyroidism1.97 (1.05–3.67)0.031.08 (0.52–2.22)0.84
Ever smoker0.92 (0.54–1.54)0.741.11 (0.60–2.05)0.74
GER therapy1.12 (0.66–1.88)0.671.38 (0.79–2.43)0.26
Chronic systemic corticosteroid therapy0.82 (0.49–1.38)0.461.39 (0.73–2.63)0.32
Immunosuppressive therapy0.74 (0.47–1.17)0.20.7 (0.35–1.4)0.31
UIP pattern+2.4 (1.21–4.76)0.011.72 (0.83–3.56)0.14
FVC % predicted0.99 (0.98–1.01)0.221 (0.97–1.02)0.76
DLCO % predicted0.97 (0.96–0.99)<0.0010.97 (0.95–0.99)0.01
Clinical domain0.56 (0.32–0.96)0.03
 Raynaud's phenomenon0.57 (0.29–1.10)0.09
Serologic domain1.89 (0.59–6.06)0.28
 ANA seropositivity0.91 (0.51–1.62)0.75
Morphological domain1.31 (0.56–3.06)0.53
 HRCT features0.58 (0.34–1.0)0.05
 SLB features0.36 (0.11–1.18)0.09
 Multicompartment features2.01 (1.19–3.38)0.009
  • HR: hazard ratio; GER: gastroesophageal reflux; UIP: usual interstitial pneumonia; FVC: forced vital capacity; DLCO: diffusion capacity of the lung for carbon monoxide; ANA: antinuclear antibody; HRCT: high-resolution computed tomography; SLB: surgical lung biopsy. #: N=143; : azathioprine n=41, mycophenolate mofetil n=19, tacrolimus n=4, and cyclophosphamide n=2; +: based on HRCT or SLB, with SLB serving as final diagnosis when discordant.